Publications by authors named "C Mascaux"

Claim this Profile
D
Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial.
Valérie Gounant, Laurent Greillier, Céline Mascaux, François Pinquie, Delphine Carmier

JTO Clin Res Rep· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
A Zer, M-J Ahn, F Barlesi, L Bubendorf, D De Ruysscher, C Mascaux

Ann Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC.
Celine Mascaux, Triparna Sen, Montse Sanchez-Cespedes, Sandra Ortiz-Cuaran, Yohan Bossé

J Thorac Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.
Alexander I Spira, Luis Paz-Ares, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux

J Thorac Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.
M Wislez, C Mascaux, J Cadranel, Q D Thomas, C Ricordel

Eur J Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis